Genitourinary Cancer News

Two phase 3 trials that evaluated a nonsurgical therapy for certain patients with bladder cancer met their primary endpoints, according to the agent’s manufacturer.

Insurance and neighborhood socioeconomic status were significant mediators of inequity in CV mortality among Black and white cancer survivors, according to a study published in the International Journal of Epidemiology.

Direct oral anticoagulants for cancer-associated thrombosis appeared associated with lower risk for venous thromboembolism recurrence and major bleeds, as well as a reduction in mortality rates, among patients with cancer.

Adolescent and young adult survivors of kidney cancer appeared at significantly increased risk for left ventricular ejection fraction, according to study results published in Journal of the National Comprehensive Cancer Network.

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

In this video, Farshid Sadeghi, MD, discussed data for a study examining cabozantinib-resistant kidney cancer at American Urological Association Annual Meeting.

In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.

In this video, Farshid Sadeghi, MD, discussed data presented on renal cell carcinoma at American Urological Association Annual Meeting.

Editor’s note: This is the fourth in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

The addition of stereotactic body radiotherapy to immune checkpoint inhibitors failed to significantly extend survival among individuals with advanced solid tumors, results of the randomized phase 2 CHEERS trial showed.